U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C31H37N5O3
Molecular Weight 527.6572
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DORAMAPIMOD

SMILES

CC1=CC=C(C=C1)N2N=C(C=C2NC(=O)NC3=CC=C(OCCN4CCOCC4)C5=C3C=CC=C5)C(C)(C)C

InChI

InChIKey=MVCOAUNKQVWQHZ-UHFFFAOYSA-N
InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37)

HIDE SMILES / InChI

Description

Doramapimod (BIRB-796) is a p38 MAPK inhibitor, relatively potent against alpha isoform. Oral doramapimod exerts anti-inflammatory potential in humans in vivo. Doramapimod has entered clinical trials for the treatment of autoimmune diseases.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.1 nM [Kd]
65.0 nM [IC50]
0.2 µM [IC50]
0.52 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
A randomised, parallel, double-blind, placebo-controlled study investigated efficacy and safety of different doses (5, 10, 20 and 30 mg) of doramapimod (BIRB-796) administered twice a day orally over 4 weeks in patients with active rheumatoid arthritis
Route of Administration: Oral
In Vitro Use Guide
1-1000 nM doramapimod (BIRB-796) inhibited LPS-induced phosphorylation of p38 MAPK in human peripheral blood mononuclear cells in a dose-related fashion